Credit Suisse Has increased its target price for Puma Biotechnology, Inc PBYI from $54 to $111, maintaining an Outperform Rating. The increased price target is based on the firm's greater sales expectations for the breast cancer treatment drug neratinib.
“We view the FDA's acceptance of neratinib's NDA as a key de-risking event,” said analyst Kennen MacKay, “further supported by management's guidance that FDA's 60-day letter indicated that no review issues have been identified at this time.”
Credit Suisse sees physician sentiment towards neratinib improving and an awareness of Imodium prophylaxis as a means of managing side effects of the drug increasing.
“We view this improving the drug's risk/reward profile and likelihood of usage in lower risk patients,” states MacKay.
Credit Suisse also hosted a physician call at 1:30 p.m. to discuss neratinib’s potential for approval and usage.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.